Association of Mosaic Chromosomal Alterations and Genetic Factors with the Risk of Cirrhosis

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2024 Jul 8

PMID 38974956

Authors

Xinyuan Ge

Lu Zhang

Maojie Liu

Xiao Wang

Xin Xu

Yuqian Yan

Chan Tian

Juan Yang

Yang Ding

Chengxiao Yu

Jing Lu

Longfeng Jiang

Qiang Wang

Qun Zhang

Ci Song

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA are structural somatic variants that indicate clonal hematopoiesis. This study aimed to investigate whether mCAs contribute to the risk of cirrhosis and modify the effect of a polygenic risk score (PRS) on cirrhosis risk prediction.

Methods: mCA call sets of individuals with European ancestry were obtained from the UK Biobank. The PRS was constructed based on 12 susceptible single-nucleotide polymorphisms for cirrhosis. Cox proportional hazard models were applied to evaluate the associations between mCAs and cirrhosis risk.

Results: Among 448,645 individuals with a median follow-up of 12.5 years, we identified 2,681 cases of cirrhosis, 1,775 cases of compensated cirrhosis, and 1,706 cases of decompensated cirrhosis. Compared to non-carriers, individuals with copy-neutral loss of heterozygosity mCAs had a significantly increased risk of cirrhosis (hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.12-1.81). This risk was higher in patients with expanded cell fractions of mCAs (cell fractions ≥10% vs. cell fractions <10%), especially for the risk of decompensated cirrhosis (HR 2.03 [95% CI 1.09-3.78] vs. 1.14 [0.80-1.64]). In comparison to non-carriers of mCAs with low genetic risk, individuals with expanded copy-neutral loss of heterozygosity and high genetic risk showed the highest cirrhosis risk (HR 5.39 [95% CI 2.41-12.07]).

Conclusions: The presence of mCAs is associated with increased susceptibility to cirrhosis risk and could be combined with PRS for personalized cirrhosis risk stratification.

References

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Laurie C, Laurie C, Rice K, Doheny K, Zelnick L, McHugh C . Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44(6):642-50. PMC: 3366033. DOI: 10.1038/ng.2271. View

Youssoufian H, Pyeritz R . Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002; 3(10):748-58. DOI: 10.1038/nrg906. View

ANTHONY P, Ishak K, Nayak N, Poulsen H, Scheuer P, Sobin L . The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 1978; 31(5):395-414. PMC: 1145292. DOI: 10.1136/jcp.31.5.395. View

Zekavat S, Lin S, Bick A, Liu A, Paruchuri K, Wang C . Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021; 27(6):1012-1024. PMC: 8245201. DOI: 10.1038/s41591-021-01371-0. View

Biesecker L, Spinner N . A genomic view of mosaicism and human disease. Nat Rev Genet. 2013; 14(5):307-20. DOI: 10.1038/nrg3424. View

Garcia C . Insights from human genetic studies of lung and organ fibrosis. J Clin Invest. 2018; 128(1):36-44. PMC: 5749497. DOI: 10.1172/JCI93556. View

Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H . Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 2006; 25(40):5581-90. DOI: 10.1038/sj.onc.1209537. View

Fleming K, Aithal G, Card T, West J . The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010; 32(11-12):1343-50. DOI: 10.1111/j.1365-2036.2010.04473.x. View

10.

Tapial S, Garcia J, Corchete L, Holowatyj A, Perez J, Rueda D . Copy neutral loss of heterozygosity (cnLOH) patterns in synchronous colorectal cancer. Eur J Hum Genet. 2020; 29(4):709-713. PMC: 8115567. DOI: 10.1038/s41431-020-00774-w. View

11.

Bycroft C, Freeman C, Petkova D, Band G, Elliott L, Sharp K . The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562(7726):203-209. PMC: 6786975. DOI: 10.1038/s41586-018-0579-z. View

12.

Mikhail F, Biegel J, Cooley L, Dubuc A, Hirsch B, Horner V . Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and.... Genet Med. 2019; 21(9):1903-1916. DOI: 10.1038/s41436-019-0545-7. View

13.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3):e1001779. PMC: 4380465. DOI: 10.1371/journal.pmed.1001779. View

14.

Dai X, Guo X . Decoding and rejuvenating human ageing genomes: Lessons from mosaic chromosomal alterations. Ageing Res Rev. 2021; 68:101342. DOI: 10.1016/j.arr.2021.101342. View

15.

Emdin C, Haas M, Ajmera V, Simon T, Homburger J, Neben C . Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. Gastroenterology. 2020; 160(5):1620-1633.e13. PMC: 8035329. DOI: 10.1053/j.gastro.2020.12.011. View

16.

Terao C, Suzuki A, Momozawa Y, Akiyama M, Ishigaki K, Yamamoto K . Chromosomal alterations among age-related haematopoietic clones in Japan. Nature. 2020; 584(7819):130-135. PMC: 7489641. DOI: 10.1038/s41586-020-2426-2. View

17.

Loh Z, Fitzsimmons R, Reid R, Ramnath D, Clouston A, Gupta P . Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. Br J Pharmacol. 2019; 176(19):3775-3790. PMC: 6780048. DOI: 10.1111/bph.14768. View

18.

OKeefe C, McDevitt M, Maciejewski J . Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010; 115(14):2731-9. PMC: 2854422. DOI: 10.1182/blood-2009-10-201848. View

19.

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

20.

Aase A, Fabbrini A, White K, Averill S, Gravely A, Melzer A . Implementation of a Standardized Template for Reporting of Incidental Pulmonary Nodules: Feasibility, Acceptability, and Outcomes. J Am Coll Radiol. 2019; 17(2):216-223. DOI: 10.1016/j.jacr.2019.11.013. View